These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38742761)

  • 1. Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).
    Wolff M; Evens R; Mertens LJ; Schmidt C; Beck J; Rutrecht H; Cherniak AD; Gründer G; Jungaberle H
    J Psychopharmacol; 2024 May; 38(5):432-457. PubMed ID: 38742761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility.
    Wolff M; Mertens LJ; Walter M; Enge S; Evens R
    J Psychopharmacol; 2022 Mar; 36(3):387-408. PubMed ID: 35253518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.
    Frymann T; Whitney S; Yaden DB; Lipson J
    Front Psychol; 2022; 13():863247. PubMed ID: 35677137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI).
    Dworatzyk K; Jansen T; Schmidt TT
    PLoS One; 2022; 17(3):e0264927. PubMed ID: 35294453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelics and Psychotherapy.
    Nayak S; Johnson MW
    Pharmacopsychiatry; 2021 Jul; 54(4):167-175. PubMed ID: 33285578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a new instrument for assessing attitudes on psychedelics in the general population.
    Žuljević MF; Buljan I; Leskur M; Kaliterna M; Hren D; Duplančić D
    Sci Rep; 2022 Oct; 12(1):18225. PubMed ID: 36309539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The individual therapy process questionnaire: development and validation of a revised measure to evaluate general change mechanisms in psychotherapy.
    Mander J
    Clin Psychol Psychother; 2015; 22(4):328-45. PubMed ID: 24604874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Phase Model of Psychotherapeutic Outcome: Validation of the "Questionnaire for the Evaluation of Psychotherapeutic Change Processes" (FEP)].
    Sembill A; Vocks S; Schöttke H
    Psychother Psychosom Med Psychol; 2016 Jan; 66(1):39-46. PubMed ID: 26764904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelics and Evidence-based Psychotherapy: A Systematic Review with Recommendations for Advancing Psychedelic Therapy Research.
    Leone L; McSpadden B; DeMarco A; Enten L; Kline R; Fonzo GA
    Psychiatr Clin North Am; 2024 Jun; 47(2):367-398. PubMed ID: 38724126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI).
    Nour MM; Evans L; Nutt D; Carhart-Harris RL
    Front Hum Neurosci; 2016; 10():269. PubMed ID: 27378878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding subjective experience in psychedelic-assisted psychotherapy: The need for phenomenology.
    Miceli McMillan R; Fernandez AV
    Aust N Z J Psychiatry; 2023 Jun; 57(6):783-788. PubMed ID: 36384307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry.
    Barber GS; Dike CC
    Psychiatr Serv; 2023 Aug; 74(8):838-846. PubMed ID: 36987705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and psychometric validation of a novel scale for measuring 'psychedelic preparedness'.
    McAlpine RG; Blackburne G; Kamboj SK
    Sci Rep; 2024 Feb; 14(1):3280. PubMed ID: 38332334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.
    Peill JM; Trinci KE; Kettner H; Mertens LJ; Roseman L; Timmermann C; Rosas FE; Lyons T; Carhart-Harris RL
    J Psychopharmacol; 2022 Jan; 36(1):31-45. PubMed ID: 34983255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Subjective Effects of Psychedelics within and Beyond WEIRD Contexts.
    Graziosi M; Singh M; Nayak SM; Yaden DB
    J Psychoactive Drugs; 2023; 55(5):558-569. PubMed ID: 37679890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a scale quantifying expectations regarding active processes in therapy: The Expectations of Active Processes in Psychotherapy Scale (EAPPS).
    Tzur Bitan D; Lazar A; Siton B
    Psychiatry Res; 2018 Sep; 267():131-139. PubMed ID: 29890376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.
    Palmer M; Maynard OM
    Harm Reduct J; 2022 Jul; 19(1):81. PubMed ID: 35871679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.